NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
05 May 2025 08:30 CEST
Issuer
NFL BIOSCIENCES S.A.
See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo